Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity

Corticosteroids are widely used to treat severe COVID-19, but in immunocompromised individuals, who are susceptible to persistent infection, long term corticosteroid use may delay viral clearance. We present a case of prolonged SARS-CoV-2 infection in a man with significantly impaired B-cell immunit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022-07, Vol.28 (7), p.971-974
Hauptverfasser: Morishita, Momoko, Suzuki, Manabu, Matsunaga, Akihiro, Ishizhima, Keishi, Yamamoto, Tsukasa, Kuroda, Yudai, Kanno, Takayuki, Tsujimoto, Yoshie, Ishida, Akane, Hashimoto, Masao, Ishii, Satoru, Takasaki, Jin, Naka, Go, Iikura, Motoyasu, Izumi, Shinyu, Suzuki, Tadaki, Maeda, Ken, Ishizaka, Yukihito, Hojo, Masayuki, Sugiyama, Haruhito
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Corticosteroids are widely used to treat severe COVID-19, but in immunocompromised individuals, who are susceptible to persistent infection, long term corticosteroid use may delay viral clearance. We present a case of prolonged SARS-CoV-2 infection in a man with significantly impaired B-cell immunity due to non-Hodgkin lymphoma which had been treated with rituximab. SARS-CoV-2 shedding persisted, despite treatment with remdesivir. Viral sequencing confirmed the persistence of the same viral strain, ruling out the possibility of reinfection. Although SARS-CoV-2 IgG, IgA and IgM remained negative throughout the treatment period, after reduction of the corticosteroid dose, PCR became negative. Long-term corticosteroid treatment, especially in immunocompromised individuals, may result in suppression of cell-mediated immunity and prolonged SARS-CoV-2 infection.
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2022.02.006